ARTBIO is developing a new class of alpha radioligand therapies that utilize Pb-212 isotopes to target and destroy cancer cells while minimizing damage to healthy tissues. This approach addresses the limitations of existing beta radioligand therapies by offering potentially improved efficacy and safety for patients with solid tumors.
Funding
$113M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Existing beta radioligand therapies for solid tumors can cause damage to healthy tissues, limiting their efficacy and safety. Current treatments often struggle to effectively target and destroy cancer cells while minimizing off-target effects.
Solution
ARTBIO is developing a novel class of alpha radioligand therapies (ARTs) using Pb-212 isotopes to selectively target and eradicate cancer cells. This approach aims to improve upon existing beta radioligand therapies by delivering potent alpha radiation directly to tumors, potentially increasing efficacy while reducing harm to surrounding healthy tissues. ARTBIO's holistic approach encompasses target identification, drug molecule selection, isotope production via AlphaDirectTM, and ART manufacturing to maximize the potential of ARTs. The company's pipeline includes multiple programs in development, with the lead program, AB001, currently in Phase 0 clinical trials for prostate cancer.
Target Audience
The primary target audience includes cancer patients with solid tumors who may benefit from more effective and safer radioligand therapies, as well as oncologists and medical professionals seeking advanced treatment options.
Features
- Utilizes Pb-212 isotopes for targeted alpha radiation delivery
- AlphaDirectTM isotope production for reliable supply
- Pipeline of ARTs with high affinity and selectivity for tumor cells
- AB001 lead program in Phase 0 clinical trials for prostate cancer
- Additional undisclosed targets (ABA, ABB, and ABC) in lead optimization and discovery phases
- Focus on specific target and drug molecule combinations for optimal ART design